Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01986933 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of CIM331 for Atopic Dermatitis Patients
A Phase 2 study of Atopic Dermatitis, sponsored by Chugai Pharmaceutical.
- Completed
- Registry status
- Phase 2
- Development phase
- 264
- Enrollment target
- 18
- Study locations
NCT01986933: Completed Phase 2 study of Atopic Dermatitis, sponsored by Chugai Pharmaceutical.
NCT01986933 is a Phase 2 study of Atopic Dermatitis that has completed, run by Chugai Pharmaceutical. The registered enrollment target is 264 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (57% lower). The trial reports 18 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01986933, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Chugai Pharmaceutical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 264 participants
- Enrollment target
- 18
- Study locations
Study Summary
To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy
Primary Outcome
Percent changes from baseline in pruritus VAS at Week 12. VAS indicates pruritus intensity in the last 24 hours, from 0 (no itch) to 10 (worst imaginable itch). When condition of pruritus improves, percent change from baseline at Week 12 indicates negative value (i.e. the higher the absolute value is, the more the condition improves).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG nemolizumab (CIM331)
Study Locations (18)
Illinois
- - Arlington Heights
- - Chicago
Kentucky
- - Louisville
- - Louisville
South Carolina
- - Charleston
- - Charleston
Alabama
- - Anniston
California
- - San Diego
Florida
- - Miami
Georgia
- - Alpharetta
Indiana
- - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2013-11 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
What the finished NCT01986933 record still lists
NCT01986933 is an interventional study that assigns participants to a tested intervention. The registered 264 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01986933 lists 18 locations in 15 states (Illinois, Kentucky, South Carolina).
Frequently Asked Questions
What is clinical trial NCT01986933 about?
NCT01986933 is a clinical study titled "A Phase 2 Study of CIM331 for Atopic Dermatitis Patients". To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy
What is the current status of trial NCT01986933?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 264 participants. The study started on 2013-11. Estimated completion is 2016-06.
What conditions does trial NCT01986933 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT01986933?
The interventions under investigation include: Placebo (OTHER), nemolizumab (CIM331) (DRUG).
Who is sponsoring clinical trial NCT01986933?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01986933 being conducted?
This trial has 18 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01986933's enrollment target sits among peer trials
264 45th of 150 higher than 106 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
- NCT04295863 · 264 participants · Phase 1
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- NCT05220202 · 264 participants · NA
MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression
- NCT05473013 · 264 participants · NA
Optimizing Digital Health Technology Interventions to Increase Skill Acquisition and Utilization
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia